Drug Trial Radar · NCT06764771
A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors
Last checked: Nov 20, 2026Latest source record: Jul 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
437
Planned (sponsor's estimate)
Start
Mar 25, 2025
Primary completion
Oct 15, 2027
Study completion Oct 15, 2027
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Jan 8, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This purpose of this study is to determine if experimental treatment with BMS-986488, alone, or in combinations is safe, tolerable, and has anti-cancer activity in patients with advanced malignant tumors.
Conditions
- Advanced Malignant Tumors
Interventions
BMS-986488Drug
Specified dose on specified days
AdagrasibDrug
Specified dose on specified days
CetuximabDrug
Specified dose on specified days
NivolumabDrug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with Adverse Events (AEs)Time frame: Until the end of the Safety Follow-up period (up to approximately 100 days after last dose)
- Number of participants with Serious AEs (SAEs)Time frame: Until the end of the Safety Follow-up period (up to approximately 100 days after last dose)
- Number of participants with AEs meeting protocol-defined Dose-Limiting Toxicity (DLT) criteriaTime frame: From first dose of study treatment until end of cycle 1 (1 Cycle = 28 Days)
- Number of participants with AEs leading to discontinuationTime frame: Until the end of the Safety Follow-up period (up to approximately 100 days after last dose)
- Number of deathsTime frame: From time of informed consent up to 52 weeks after end of treatment visit
Locations
8 sites in 3 countries. Site status is shown where the registry gives one.
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey · Recruiting
Local Institution - 0020
Allentown, Pennsylvania · Active not recruiting
The West Clinic, PLLC dba West Cancer Center
Germantown, Tennessee · Recruiting
Local Institution - 0025
Dallas, Texas · Withdrawn
Local Institution - 0031
Brisbane, Queensland, Australia · Active not recruiting
BC Cancer Vancouver
Vancouver, British Columbia, Canada · Recruiting
Local Institution - 0015
Montreal, Quebec, Canada · Not yet recruiting
Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus
Québec, Quebec, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.